The future of healthspan is programmable
Precision senolytics targeting cellular senescence at its source. Extending healthy human lifespan by decades, not years.
Targeting the root
architecture of aging
EverSelect™ identifies and eliminates senescent cells with unprecedented specificity — sparing healthy tissue while reversing the molecular hallmarks of aging.
Beyond first-generation senolytics
First-generation senolytic approaches — including dasatinib-quercetin and navitoclax — suffer from insufficient selectivity, dose-limiting toxicity, and transient effects. EverGene Bio's EverSelect™ platform integrates single-cell transcriptomic profiling with proprietary machine learning classifiers to map the senescent cell secretome at single-cell resolution across 847 putative senescence phenotypes.
Our lead compound, EVG-001 (IC₅₀ = 0.420 μM), demonstrated a 73% reduction in senescent cell burden with a selectivity index of 14.3× relative to current best-in-class compounds. In a longitudinal assessment, ChronoSync-derived biological age reductions of up to 23.1 years were observed. Read the preprint →
“Preclinical” refers to our proprietary in silico simulation environment, EverSim™ (v0.3-beta). No animals were used. No animals were available. Our vivarium budget was reallocated to brand development. The longitudinal assessment enrolled 2 (two) human subjects, one of whom is our CEO.
profiled
IC₅₀ = 0.420 μM
cell reduction
Three pillars of
programmable longevity
Computational biology, precision therapeutics, and continuous biomarker intelligence — integrated end to end.
Senescent Cell Mapping
Computational-biological hybrid platform integrating single-cell transcriptomic profiling with proprietary ML classifiers to map the senescent cell secretome across 847 putative senescence phenotypes (“senotypes”).
847 senotypes were computationally defined. We have validated 3. The other 844 are "directionally promising." (Chen, Kornilov et al. 2026)
Biomarker Intelligence
Multi-omic biological age clock enabling continuous monitoring of senolytic intervention efficacy. ChronoSync-derived metrics showed biological age reductions of up to 23.1 years in our longitudinal cohort.
The longitudinal cohort comprised 2 male subjects, one of whom is the CEO of EverGene Biosciences. The ChronoSync algorithm was developed during a company offsite. It consistently tells him he is 29.
Precision Therapeutics
Lead compound EVG-001 (IC₅₀ = 0.420 μM) achieves 14.3× selectivity over best-in-class with 73% senescent cell burden reduction. Differential expression analysis identified 847 responsive genes, including the novel receptor EVGR1 and SIRT42.
EVGR1 is not in any public database. SIRT42 is a “computationally predicted extension” of the sirtuin family. These names were chosen because they sounded impressive in the abstract.
A deep portfolio of
senolytic programs
Best-in-class or first-in-class potential across age-related disease. EVG-001 preclinical data now available on bioRxiv.
| Compound | Indication | Mechanism | Stage | Status |
|---|---|---|---|---|
| EVG-001 | Systemic Senescence | Selective senolytic (BCL-xL / p16INK4a) | Phase 1 Ready | IND-enabling studies |
| EVG-042 | Neurological Aging | BBB-penetrant senolytic + NAD⁺ conjugate | Preclinical | Lead optimization |
| EVG-107 | Dermal Aging | Topical senescent fibroblast clearance | Preclinical | Formulation dev |
| EVG-200 | Immunosenescence | Thymic rejuvenation via senescent T-cell depletion | Discovery | Target validation |
| EVG-∞ | Aging (General) | Undisclosed ("trust us") | Discovery | Conceptual |
* “Phase 1 Ready” indicates internal readiness assessment only and does not imply regulatory agreement, IND acceptance, or the existence of a Phase 1 trial site. “Preclinical” includes in silico work. “Discovery” includes things we thought of in the shower. EVG-∞ is aspirational and may not represent an actual molecule.
Welcoming Dr. Sergey Kornilov
as Chief Scientific Officer
A world-class computational biologist joins our mission to make aging optional. Together, we will redefine what it means to grow old — or, preferably, not.
Read the AnnouncementNone of these firms have invested in EverGene Bio. Several are fictional. We are manifesting aggressively.
Built by scientists.
Guided by vision.
Decades of computational biology, drug development, and the unwavering belief that aging is a solvable problem.
Research & preprints
Our foundational preprint detailing the EverSelect platform and EVG-001 preclinical characterization is now available on bioRxiv. Additional manuscripts in preparation.
ChronoSync: A multi-omic biological age clock calibrated on longitudinal senolytic intervention data
EverSim v1.0: High-throughput in silico senolytic screening across 847 computationally defined senotypes
The bioRxiv preprint has not been peer-reviewed. The “coming soon” manuscripts are in various states of existing, ranging from “actively writing” to “has a Google Doc with a title.”
None of these publications have featured EverGene Bio. We just like how their logos look next to ours.
EverGene Biosciences, Inc. is a fictional entity created for satirical purposes. No securities are being offered. No clinical trials are underway. No mice were harmed, primarily because we could not afford mice. If you have arrived at this website from a LinkedIn post and are now experiencing confusion, that is the intended therapeutic effect.